Label: LACTULOSE solution

  • NDC Code(s): 0116-4005-08, 0116-4005-10, 0116-4005-11, 0116-4005-15, view more
    0116-4005-16, 0116-4005-30, 0116-4005-32, 0116-4005-40, 0116-4005-41
  • Packager: Xttrium Laboratories, Inc.
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Abbreviated New Drug Application

Drug Label Information

Updated March 21, 2023

If you are a consumer or patient please visit this version.

  • LACTULOSE SOLUTION, USP

    10g/15mL

    For Oral Administration

    Rx Only

  • DESCRIPTION

    ​Lactulose solution is a synthetic disaccharide in solution form for oral administration. Each 15 mL of lactulose contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose, and 1.2 g or less of other sugars). Also contains water, D&C Yellow No. 10, and FD&C Yellow No. 6. The pH range is 2.5 to 6.5.

    Lactulose solution is a colonic acidifier which promotes laxation.

    The chemical name for lactulose is 4-O-ß-D-galactopyranosyl-D-fructofuranose. It has the following structural formula:

    lactulose structure

    C 12H 220 11

    The molecular weight is 342.30. It is freely soluble in water.

  • CLINICAL PHARMACOLOGY

    Lactulose is poorly absorbed from the gastrointestinal tract and no enzyme capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue. As a result, oral doses of lactulose reach the colon virtually unchanged. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool.

    Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be slow, 24 to 48 hours may be required to produce the desired bowel movement.

    Lactulose given orally to man and experimental animals resulted in only small amounts reaching the blood. Urinary excretion has been determined to be 3% or less and is essentially complete within 24 hours.

  • INDICATIONS AND USAGE

    For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.

  • CONTRAINDICATIONS

    Since lactulose solution contains galactose (less than 1.6 g/15 mL), it is contraindicated in patients who require a low galactose diet.

  • WARNINGS

    A theoretical hazard may exist for patients being treated with lactulose solution who may be required to undergo electrocautery procedures during proctoscopy or colonoscopy. Accumulation of H2 gas in significant concentration in the presence of an electrical spark may result in an explosive reaction. Although this complication has not been reported with lactulose, patients on lactulose therapy undergoing such procedures should have a thorough bowel cleansing with a non-fermentable solution. Insufflation of CO 2 as an additional safeguard may be pursued but is considered to be a redundant measure.

  • PRECAUTIONS

    General

    Since lactulose solution contains galactose (less than 1.6 g/15 mL) and lactose (less than 1.2 g/15 mL), it should be used with caution in diabetics.

    Information for Patients

    In the event that an unusual diarrheal condition occurs, contact your physician.

    Laboratory Tests

    Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically.

    Drug Interactions

    Results of preliminary studies in humans and rats suggest that non-absorbable antacids given concurrently with lactulose may inhibit the desired lactulose-induced drop in colonic pH. Therefore, a possible lack of desired effect of treatment should be taken into consideration before such drugs are given concomitantly with lactulose solution.

    Carcinogenesis, Mutagenesis, Impairment of Fertility

    There are no known human data on long-term potential for carcinogenicity, mutagenicity, or impairment of fertility.

    There are no known animal data on long-term potential for mutagenicity.

    Administration of lactulose solution in the diet of mice for 18 months in concentrations of 3 and 10 percent (v/w) did not produce any evidence of carcinogenicity.

    In studies in mice, rats, and rabbits, doses of lactulose solution up to 6 or 12 mL/kg/day produced no deleterious effects in breeding, conception, or parturition.

    Pregnancy

    Teratogenic Effects

    Reproduction studies have been performed in mice, rats, and rabbits at doses up to 3 or 6 times the usual human oral dose and have revealed no evidence of impaired fertility or harm to the fetus due to lactulose. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

    Nursing Mothers

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lactulose solution is administered to a nursing woman.

    Pediatric Use

    Safety and effectiveness in pediatric patients have not been established.

  • ADVERSE REACTIONS

    Precise frequency data are not available.

    Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia, and hypernatremia.

    Nausea and vomiting have been reported.

    To report SUSPECTED ADVERSE REACTIONS, contact Xttrium Laboratories, Inc. at 1-800-587-3721 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

  • OVERDOSAGE

    Signs and Symptoms

    There have been no reports of accidental overdosage. In the event of overdosage, it is expected that diarrhea and abdominal cramps would be the major symptoms. Medication should be terminated.

    Oral LD50

    The acute oral LD50 of the drug is 48.8 mL/kg in mice and greater than 30 mL/kg in rats.

    Dialysis

    Dialysis data are not available for lactulose. Its molecular similarity to sucrose, however, would suggest that it should be dialyzable.

  • DOSAGE AND ADMINISTRATION

    The usual dose is 1 to 2 tablespoonfuls (15 to 30 mL, containing 10 g to 20 g of lactulose) daily. The dose may be increased to 60 mL daily if necessary. Twenty-four to 48 hours may be required to produce a normal bowel movement.

    NOTE: Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.

  • HOW SUPPLIED

    Lactulose Solution, USP 10 g/15 mL is a colorless to yellow, unflavored solution available in the following container sizes:

    15 mL unit dose white cups in trays of 10 cups (NDC 0116-4005-15)

    30 mL unit dose white cups in trays of 10 cups (NDC 0116-4005-30)

    8 fl. oz. (237 mL) white bottles (NDC 0116-4005-08)

    16 fl. oz. (473 mL) white bottles (NDC 0116-4005-16)

    32 fl. oz. (946 mL) white bottles (NDC 0116-4005-32)

    Lactulose solution contains lactulose 667 mg/mL (10 g/15 mL).

    Store at 20 ° to 25 °C (68 ° to 77 °F) [see USP Controlled Room Temperature]. Do not freeze.

    Under recommended storage conditions, a normal darkening of color may occur. Such darkening is characteristic of sugar solutions and does not affect therapeutic action.

    Prolonged exposure to temperatures above 30 °C (86 °F) or to direct light may cause extreme darkening and turbidity which may be pharmaceutically objectionable. If this condition develops, do not use.

    Prolonged exposure to freezing temperatures may cause change to a semisolid, too viscous to pour. Viscosity will return to normal upon warming to room temperature.

    Dispense in original container or in a tight, light-resistant container as defined in the USP, with a child-resistant closure.

    To The Pharmacist: When ordering this product, include the product number (or NDC) in the description.

  • SPL UNCLASSIFIED SECTION

    Rx Only

    Revised: March 2022

    Distributed by:

    Xttrium Laboratories, Inc.

    1200 E. Business Center Dr.

    Mount Prospect, IL 60056

  • LACTULOSE 8OZ (237 mL)

    NDC 0116-4005-08

    LACTULOSE SOLUTION, USP

    10g/15mL

    INDICATIONS: For the Treatment of Constipation

    Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
    and 1.2 g or less of other sugars). Also contains water, D&C Yellow No. 10, and FD&C Yellow No. 6.


    USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
    Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
    slow, 24 to 48 hours may be required to produce a normal bowel movement.
    Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
    Dispense in original container or in a tight, light-resistant container with child-resistant closure.
    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
    Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
    See accompanying product information.
    Keep tightly closed.
    PHARMACIST: When ordering this product, include the NDC number in the description.
    Distributed by:
    Xttrium Laboratories, Inc.
    1200 E. Business Center Dr.
    Mount Prospect, IL 60056

    Rx Only

    Net Contents: 8 fl oz (237mL)

    4005LACT08LBL

    Rev. 03/2022

    LACT 08 PDP

    LACT 08 Prescribing 1

    LACT 08 Prescribing 2

  • LACTULOSE 16OZ (473 mL)

    NDC 0116-4005-16

    LACTULOSE SOLUTION, USP

    10g/15mL

    INDICATIONS: For the Treatment of Constipation

    Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
    and 1.2 g or less of other sugars). Also contains water, D&C Yellow No. 10, and FD&C Yellow No. 6.


    USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
    Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
    slow, 24 to 48 hours may be required to produce a normal bowel movement.
    Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
    Dispense in original container or in a tight, light-resistant container with child-resistant closure.
    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
    Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
    See accompanying product information.
    Keep tightly closed.

    PHARMACIST: When ordering this product, include the NDC number in the description.


    Distributed by:
    Xttrium Laboratories, Inc.
    1200 E. Business Center Dr.
    Mount Prospect, IL 60056

    Rx Only

    Net Contents: 16 fl oz (473mL)

    4005LACT16LBL

    Rev. 03/2022

    Lactulose 16 PDPLactulose 16 Prescribing 1Lactulose 16 Prescribing 2

  • LACTULOSE 32OZ (946 mL)

    NDC 0116-4005-32

    LACTULOSE SOLUTION, USP

    10g/15mL

    INDICATIONS: For the Treatment of Constipation

    Each 15 mL of lactulose solution contains: 10 g lactulose (and less than 1.6 g galactose, less than 1.2 g lactose,
    and 1.2 g or less of other sugars). Also contains water, D&C Yellow No. 10, and FD&C Yellow No. 6.


    USUAL ADULT DOSAGE: 1 to 2 tablespoonfuls (15 to 30 mL) daily. See attached insert for full prescribing information.
    Since lactulose does not exert its effect until it reaches the colon, and since transit time through the colon may be
    slow, 24 to 48 hours may be required to produce a normal bowel movement.
    Some patients have found that lactulose solution may be more acceptable when mixed with fruit juice, water, or milk.
    Dispense in original container or in a tight, light-resistant container with child-resistant closure.
    Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Do not freeze.
    Product may darken slightly but therapeutic action is not affected. Do not use if extreme darkening or turbidity occurs.
    See accompanying product information.
    Keep tightly closed.


    PHARMACIST: When ordering this product, include the NDC number in the description.


    Distributed by:
    Xttrium Laboratories, Inc.
    1200 E. Business Center Dr.
    Mount Prospect, IL 60056

    Rx Only

    Net Contents: 32 fl oz (946 mL)

    4005LACT32LBL

    Rev. 03/2022

    Lactulose 32 PDPLactulose 32 Prescribing 1Lactulose 32 Prescribing 2

  • LACTULOSE 15mL UNIT DOSE CUP

    UNIT DOSE

    Delivers 15mL

    NDC 0116-4005-15

    LACTULOSE SOLUTION, USP

    10g/15mL

    Rx Only

    Xttrium Laboratories, Inc.

    Mount Prospect, IL 60056

    4005LACT15LID

    4005LACT15LID

  • LACTULOSE 30 mL UNIT DOSE CUP

    UNIT DOSE

    Delivers 30mL

    NDC 0116-4005-30

    LACTULOSE SOLUTION, USP

    20g/30mL

    Rx Only

    Xttrium Laboratories, Inc.

    4005LACT30LID

    4005LACT30LID

  • Prescribing Information Insert

    Lactulose Insert-1Lactulose Insert-2Lactulose Insert-3

  • INGREDIENTS AND APPEARANCE
    LACTULOSE 
    lactulose solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC:0116-4005
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    LACTULOSE (UNII: 9U7D5QH5AE) (LACTULOSE - UNII:9U7D5QH5AE) LACTULOSE10 g  in 15 mL
    Inactive Ingredients
    Ingredient NameStrength
    D&C YELLOW NO. 10 (UNII: 35SW5USQ3G)  
    WATER (UNII: 059QF0KO0R)  
    FD&C YELLOW NO. 6 (UNII: H77VEI93A8)  
    Product Characteristics
    Coloryellow (Colorless to yellow) Score    
    ShapeSize
    FlavorImprint Code
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC:0116-4005-08237 mL in 1 BOTTLE; Type 0: Not a Combination Product07/01/2022
    2NDC:0116-4005-16473 mL in 1 BOTTLE; Type 0: Not a Combination Product07/01/2022
    3NDC:0116-4005-32946 mL in 1 BOTTLE; Type 0: Not a Combination Product07/01/2022
    4NDC:0116-4005-10100 in 1 CASE07/01/2022
    4NDC:0116-4005-4040 in 1 CASE
    410 in 1 TRAY
    4NDC:0116-4005-1515 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product
    5NDC:0116-4005-11100 in 1 CASE07/01/2022
    5NDC:0116-4005-4140 in 1 CASE
    510 in 1 TRAY
    5NDC:0116-4005-3030 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product
    6NDC:0116-4005-1515 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product07/01/2022
    7NDC:0116-4005-3030 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product07/01/2022
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA07591107/01/2022
    Labeler - Xttrium Laboratories, Inc. (007470579)
    Registrant - Xttrium Laboratories, Inc. (007470579)
    Establishment
    NameAddressID/FEIBusiness Operations
    Xttrium Laboratories, Inc.007470579manufacture(0116-4005)